DK2235007T3 - Ikke-steroide mineralocorticoid-receptorantagonister af 6h-dibenz0 [b,e] oxepin - Google Patents

Ikke-steroide mineralocorticoid-receptorantagonister af 6h-dibenz0 [b,e] oxepin

Info

Publication number
DK2235007T3
DK2235007T3 DK08866835.5T DK08866835T DK2235007T3 DK 2235007 T3 DK2235007 T3 DK 2235007T3 DK 08866835 T DK08866835 T DK 08866835T DK 2235007 T3 DK2235007 T3 DK 2235007T3
Authority
DK
Denmark
Prior art keywords
oxepin
dibenzo
steroid
receptor antagonists
mineralocorticoid receptor
Prior art date
Application number
DK08866835.5T
Other languages
Danish (da)
English (en)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2235007(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2235007T3 publication Critical patent/DK2235007T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK08866835.5T 2007-12-19 2008-12-09 Ikke-steroide mineralocorticoid-receptorantagonister af 6h-dibenz0 [b,e] oxepin DK2235007T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
DK2235007T3 true DK2235007T3 (da) 2012-12-17

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08866835.5T DK2235007T3 (da) 2007-12-19 2008-12-09 Ikke-steroide mineralocorticoid-receptorantagonister af 6h-dibenz0 [b,e] oxepin

Country Status (33)

Country Link
US (1) US7994164B2 (enExample)
EP (2) EP2235007B1 (enExample)
JP (1) JP5562866B2 (enExample)
KR (1) KR101254382B1 (enExample)
CN (1) CN101903377B (enExample)
AR (1) AR069554A1 (enExample)
AU (1) AU2008343524B2 (enExample)
BR (1) BRPI0820805A2 (enExample)
CA (1) CA2710409C (enExample)
CL (1) CL2008003600A1 (enExample)
CO (1) CO6300953A2 (enExample)
DK (1) DK2235007T3 (enExample)
DO (1) DOP2010000185A (enExample)
EA (1) EA017668B1 (enExample)
EC (2) ECSP10010266A (enExample)
ES (2) ES2396605T3 (enExample)
GT (1) GT201000179A (enExample)
HR (1) HRP20120916T1 (enExample)
IL (1) IL206353A (enExample)
MA (1) MA31910B1 (enExample)
MX (1) MX2010006911A (enExample)
MY (1) MY150474A (enExample)
NZ (1) NZ586300A (enExample)
PE (1) PE20091057A1 (enExample)
PL (1) PL2235007T3 (enExample)
PT (1) PT2235007E (enExample)
RS (1) RS52594B (enExample)
SI (1) SI2235007T1 (enExample)
TN (1) TN2010000292A1 (enExample)
TW (1) TWI431010B (enExample)
UA (1) UA100131C2 (enExample)
WO (1) WO2009085584A1 (enExample)
ZA (1) ZA201004257B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP5570536B2 (ja) * 2009-03-12 2014-08-13 イーライ リリー アンド カンパニー 鉱質コルチコイド受容体アンタゴニストおよび使用方法
CA2796307A1 (en) 2010-05-10 2011-11-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
AP2015008843A0 (en) 2013-05-02 2015-11-30 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
SI3160948T1 (sl) 2014-06-30 2020-06-30 Astrazeneca Ab Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida
CA2963683A1 (en) * 2014-11-21 2016-05-26 Eli Lilly And Company 1,2-benzothiazole compounds for the treatment of kidney disorders
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
MX391602B (es) * 2016-09-24 2025-03-21 Novo Nordisk As Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
DE3730258A1 (de) 1986-09-10 1988-04-07 Canon Kk Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
EP1448566B3 (en) * 2001-11-21 2009-04-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
ES2308296T3 (es) 2003-12-19 2008-12-01 Eli Lilly And Company Modulares del receptor nuclear de hormonas esteroideas triciclicas.
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
KR101368228B1 (ko) 2004-11-10 2014-02-27 인사이트 코포레이션 락탐 화합물 및 약제로서의 이의 용도
AP2527A (en) 2006-10-31 2012-12-06 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptorantagonists
EP2142194A1 (en) 2007-03-29 2010-01-13 N.V. Organon Mineralocorticoid receptor antagonists
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
CA2711887A1 (en) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro-1h-pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists
JP5570536B2 (ja) 2009-03-12 2014-08-13 イーライ リリー アンド カンパニー 鉱質コルチコイド受容体アンタゴニストおよび使用方法

Also Published As

Publication number Publication date
SI2235007T1 (sl) 2013-01-31
ES2459318T3 (es) 2014-05-09
KR20100082866A (ko) 2010-07-20
MX2010006911A (es) 2010-10-05
ECSP12012048A (es) 2012-08-31
CA2710409C (en) 2012-11-06
US20090163472A1 (en) 2009-06-25
AU2008343524A1 (en) 2009-07-09
CA2710409A1 (en) 2009-07-09
IL206353A (en) 2014-06-30
TW200930721A (en) 2009-07-16
PL2235007T3 (pl) 2013-03-29
EA017668B1 (ru) 2013-02-28
CN101903377A (zh) 2010-12-01
ZA201004257B (en) 2011-11-30
JP2011507868A (ja) 2011-03-10
EP2537845A1 (en) 2012-12-26
EP2537845B1 (en) 2014-03-19
GT201000179A (es) 2012-04-16
TN2010000292A1 (en) 2011-11-11
US7994164B2 (en) 2011-08-09
PT2235007E (pt) 2013-01-22
RS52594B (sr) 2013-04-30
EA201070762A1 (ru) 2010-12-30
UA100131C2 (uk) 2012-11-26
NZ586300A (en) 2012-06-29
TWI431010B (zh) 2014-03-21
MA31910B1 (fr) 2010-12-01
KR101254382B1 (ko) 2013-04-15
WO2009085584A1 (en) 2009-07-09
CN101903377B (zh) 2014-07-09
JP5562866B2 (ja) 2014-07-30
AU2008343524B2 (en) 2012-03-08
MY150474A (en) 2014-01-30
IL206353A0 (en) 2010-12-30
HRP20120916T1 (hr) 2012-12-31
PE20091057A1 (es) 2009-07-20
CL2008003600A1 (es) 2010-02-19
DOP2010000185A (es) 2010-09-15
AR069554A1 (es) 2010-02-03
EP2235007A1 (en) 2010-10-06
HK1144284A1 (en) 2011-02-11
CO6300953A2 (es) 2011-07-21
ES2396605T3 (es) 2013-02-22
BRPI0820805A2 (pt) 2015-06-16
EP2235007B1 (en) 2012-10-31
ECSP10010266A (es) 2010-07-30

Similar Documents

Publication Publication Date Title
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
EP1981902A4 (en) ANTAGONISTS OF NOGO RECEPTORS
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
ZA201004257B (en) 6h-dibenzo[b,e]oxepine derived nonsteroidal mineralocorticoid receptor antagonists
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
DK2081951T3 (da) Progesteron-receptorantagonister
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
BRPI0821784A2 (pt) receptor de navegação
EP1978022A4 (en) CHROME COMPOUNDS
DK2129654T3 (da) Antagonister af glucagonreceptoren
EP2214676A4 (en) SUBSTITUTED DIAZEPANES AS ANTAGONISTS OF OREXIN RECEPTORS
DK2009992T3 (da) Il-8 receptor-antagonister
EP2004654A4 (en) Kinase Antagonists
EP2350060A4 (en) Melanocortin receptor AGONISTS
EP2362779A4 (en) CXCR4 RECEPTOR COMPOUNDS
EP2379510A4 (en) quinazolinone
BRPI0810926A2 (pt) Antagonista de crig
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
CU23857B1 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
BRPI0720078A2 (pt) 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a)
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
DE602007008831D1 (de) Cyclohexyl-sulfonamid-derivate mit h3-rezeptoraktivität